Thursday, May 13, 2021

Catabasis Pharmaceuticals, Inc. (CATB) Stock Price Trending Upwards Following Developments

Catabasis Pharmaceuticals, Inc. (CATB) stock prices enjoyed an 8.48% uptrend as of market close on April 19th, 2021, settling into a price of USD$2.43 per share. Subsequent pre-market fluctuations saw CATB stock prices climb further to hit UDS$2.44, a 0.41% increase.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



CATB Acquires Quellis

In January 2021, Quellis Biosciences Inc. was acquired by CATB in an agreement wherein a combination of CATB’s common and Series X Preferred Stock were traded for all of Quellis’ outstanding equity interests. Quellis is a privately-held biopharmaceutical company that focuses on discovering new molecules that are best-in-class and could treat rare diseases.

CATB Raises Capital


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Concurrently, CATB started a PIPE (private investment in public equity), which offers shares of its Series X Preferred Stock to current and prospective investors. The expected proceeds from this move come out to USD$110 million, with each Series X Preferred Stock being valued at USD$3,093. Each Preferred Stock share can be converted into 1,000 shares of CATB common stock, each of which will be priced at USD$3.09.

Allocation of Generated Capital

The generated capital will be put towards funding the completion of CATB’s IND-enabling studies, alongside Phase 1a and Phase 1b/2 clinical trials of its lead program QLS-215, which aims to treat angioedema. With operations expected to run through to 2023, CATB anticipates cash proceeds in the vicinity of USD$150 million being generated.

CATB Stock Situation

Following the acquisition of Quellis and the closing of the private placement, CATB had roughly 23.4 million shares of its common stock and roughly 86,000 shares of its Series X Preferred Stock outstanding. Should the Preferred Stock shares be converted into common stock shares, CABT will have roughly 109.5 million shares outstanding.

2020 Financial Reports

In the release of their financial reports for the year ended 30th December 2021, CATB reported USD$44.9 million in cash, cash equivalents and short-term investments. With the USD$104 million generated from the private placement after the deduction of costs associated with the offering, CATB finds itself with enough cash to fund its operation plan as it stands through to 2023.

Investing in R&D

With USD$5.7 million going towards research and development in Q4 2020, CATB is shown to be gradually investing more money in their R&D. This is indicated by the increase in Q4 2020 from the USD$4.3 million that was invested in R&D in Q4 2019. 2020 reported R&D costs for the whole year at USD$25.6 million, while costs for 2019 were USD$18.3 million.

CATB’s Future Outlook

With the acquisition of Quellis and the strong financial foothold offered by the private placement, CATB finds itself in a prime position to leverage its resources to increase shareholder value. How their clinical trials and product development proceed will determine the long-term future of the company.

Latest news

What is behind the fall of Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock?

Torchlight Energy Resources, Inc. (NASDAQ: TRCH), a growth oil and gas exploration company specializing in the acquisition and development of highly profitable domestic oil...

Eros STX Global Corporation (ESGC) stock is declining: Here is the reason why?

Eros STX Global Corporation (NYSE ESGC) a global multinational media company that acquires, produces, and distributes films, television shows, and digital content issued its...

Yum China Holdings Inc. (YUMC): The Most Important Numbers You Should Know

Yum China Holdings Inc. (YUMC), which operates Taco Bell Restaurants, KFC Restaurants, and Pizza Hut Restaurants in China, has published its first-quarter report for...

Why shares of Akerna Corp. (KERN) stock are up today?

Akerna (KERN), a cannabis technology company focusing to connect data points in the global cannabis supply chain and developer of the cannabis industry's first...

Related news

What is behind the fall of Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock?

Torchlight Energy Resources, Inc. (NASDAQ: TRCH), a growth oil and gas exploration company specializing in the acquisition and development of highly profitable domestic oil...

Eros STX Global Corporation (ESGC) stock is declining: Here is the reason why?

Eros STX Global Corporation (NYSE ESGC) a global multinational media company that acquires, produces, and distributes films, television shows, and digital content issued its...

Yum China Holdings Inc. (YUMC): The Most Important Numbers You Should Know

Yum China Holdings Inc. (YUMC), which operates Taco Bell Restaurants, KFC Restaurants, and Pizza Hut Restaurants in China, has published its first-quarter report for...

Why shares of Akerna Corp. (KERN) stock are up today?

Akerna (KERN), a cannabis technology company focusing to connect data points in the global cannabis supply chain and developer of the cannabis industry's first...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.